Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHH-1V booster versus Tozinameran in adults fully vaccinated against COVID-19, with open-label PHH-1V extension
2021-005226-26Phase 2Active
- Sponsor
- HIPRA
- Start
- Nov 2021
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PHH-1V in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by HIPRA. Primary endpoints: Primary immunogenicity endpoint (Part A), Primary safety endpoint (Part A) and 2 more. Started Nov 2021; status: active.
02
Drugs
PHH-1V
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-005226-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005226-26.